Waverton Investment Management Ltd Takes $48.98 Million Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Waverton Investment Management Ltd bought a new position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 626,507 shares of the company’s stock, valued at approximately $48,977,000. Waverton Investment Management Ltd owned 0.14% of GE HealthCare Technologies as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. LGT Financial Advisors LLC grew its stake in shares of GE HealthCare Technologies by 1,673.3% during the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the period. Capital Performance Advisors LLP purchased a new stake in GE HealthCare Technologies during the third quarter worth $26,000. Ashton Thomas Securities LLC acquired a new stake in GE HealthCare Technologies during the third quarter valued at $26,000. Darwin Wealth Management LLC purchased a new position in GE HealthCare Technologies in the third quarter valued at $31,000. Finally, Continuum Advisory LLC raised its position in shares of GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after acquiring an additional 168 shares during the period. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on GEHC shares. Wells Fargo & Company lifted their price target on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Citigroup boosted their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, GE HealthCare Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Price Performance

GE HealthCare Technologies stock opened at $91.09 on Monday. The company has a fifty day simple moving average of $85.05 and a 200-day simple moving average of $85.90. The firm has a market capitalization of $41.66 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 3.19 and a beta of 1.15. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. On average, equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.